US approves Alzheimer’s drug that modestly slows disease
Joy Snider, MD, PhD, professor of neurology
People who haven’t had COVID will likely catch XBB.1.5 – and many will get reinfected, experts say
Ziyad Al-Aly, MD, assistant professor of medicine
Eisai, Biogen get U.S. FDA approval for Alzheimer’s drug, apply for full approval
Erik Musiek, MD, PhD, assistant professor of neurology
‘We’re Going to Need Everybody’: Recordings Captured Response to N.F.L. Crisis
Matthew Matava, MD, professor of orthopedic surgery
Making sweat feel spiritual didn’t start with SoulCycle – a religion scholar explains
The next time you hear a friend assert that fitness is their new religion, know that it might not be just hyperbole. Rather, it reflects how religious meanings attached to the body have endured, transformed – and are now available for purchase at the nearest fitness studio, writes Cody Musselman.
Why layoffs are picking up at small businesses
Glenn MacDonald, the John M. Olin Distinguished Professor of Economics and Strategy
‘Are Twitter’s troubles the beginning of the end of social media?’
Ian Bogost, the Barbara and David Thomas Distinguished Professor, takes part in an episode of the New Republic podcast “The Politics of Everything” to discuss the tumult at Twitter and why we should welcome the end of social media.
As decision on new Alzheimer’s drug nears, Biogen aims for redemption
Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology
Participation in Dry January is growing. Can it lead to ‘mindful drinking’?
Carrie Mintz, MD, assistant professor of psychiatry
U.S. workers are becoming more diverse in race, ethnicity and age — but companies aren’t keeping up
Adia Harvey Wingfield, the Mary Tileston Hemenway Professor of Arts & Sciences
View More Stories